Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone).

Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model.

Results Ten RCTs (n=1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD=−10.62, 95% CI=−17.67 to −3.560, p=0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR=1.373, 95% CI=1.088–1.734, p=0.008, NNH=11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone.

Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.

Key words

schizophrenia - antipsychotic - blonanserin - systematic review - meta-analysis

• References

• 1 Li H, Yao C, Shi J. et al. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. J Psychiatr Res 2015; 69: 102-109
• 2 Kishi T, Matsuda Y, Matsunaga S. et al. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatr Dis Treat 2016; 12: 3041-3049
• 3 Kishi T, Matsuda Y, Nakamura H. et al. Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 2013; 47: 149-154
• 4 Oka M, Noda Y, Ochi Y. et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 1993; 264: 158-165
• 5 Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2014; 9: e88049
• 6 Kishi T, Ikuta T, Matsunaga S. et al. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: A network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat 2017; 13: 1281-1302
• 7 Kishi T, Matsuda Y, Iwata N. The position of blonanserin as a treatment for schizophrenia. Asia Pac Psychiatry 2014; 6: 462
• 8 Sanada K, Iwanami A, Saito K. Safety of blonanserin (BNS) and paliperidone extended-release (PAL-ER) in patients with acute schizophrenia. European College of Neuropsychopharmacology 26th annual meeting. Barcelona, Spain 2013
• 9 Yanagimoto H, Morita K, Syoji Y et al. Comparison of drug attitude and adherence between blonanserin and risperidone in patients with schizophrenia. The Japanese Society of Clinical Neuropsychopharmacology 25th annual meeting; 2015
• 10 Deepak TS, Raveesh BN, Parashivamurthy BM. et al. Clinical assessment of weight gain with atypical antipsychotics – blonanserin vs amisulpride. J Clin Diagn Res 2015; 9: FC07-FC10
• 11 Hori H, Katsuki A, Atake K et al. Blonanserin versus aripiprazole for treatment of Japanese schizophrenia patients: A randomized control trial. European College of Neuropsychopharmacology Workshop for Junior Scientists in Europe. Nice, France 2015
• 12 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339: b2535
• 13 Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. Br J Psychiatry Suppl 1989; 7: 59-67
• 14 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration. 2011; Accessed at: www.cochrane-handbook.org
• 15 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 16 Leucht S, Cipriani A, Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 17 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 18 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 19 Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463
• 20 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996; 17: 1-12
• 21 Garcia E, Robert M, Peris F. et al. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625
• 22 Yang J, Bahk WM, Cho HS. et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 2010; 33: 169-175
• 23 Murasaki M. Clinical evaluation of blonanserin for schizophrenia: A double-blind trial comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 2007; 10: 2059Y2079
• 24 Miura S. Clinical evaluation of blonanserin for schizophrenia – a randomized study comparing blonanserin with riperidone. Jpn J Clin Psychopharmacol 2008; 11: 297-314
• 25 Moreno SG, Sutton AJ, Ades AE. et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol 2009; 9: 2